Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ankur Goel

Colon & Rectal Surgery Augusta, GA Medical Doctor

NPI 1598993016 CMS profile 921238

1430 Harper St Ste B, Augusta, GA 30901

Open in the dashboard

General payments

$19,223

70 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ankur Goel of Augusta, GA is reported in the CMS Open Payments database as having received $19,223 across 70 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Colon & Rectal Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $264 6
2024 General $4,645 19
2023 General $458 14
2022 General $6,210 10
2021 General $6,817 14
2019 General $828 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ankur Goel
  • Colon & Rectal Surgery median
  • Middle half of Colon & Rectal Surgery
  • National median

In program year 2025, general payments to Ankur Goel were reported at $264. Among 1,481 Colon & Rectal Surgery profiles paid that year, the median was $317 and the middle half received between $109 and $1,248.

Show as a table
Year Ankur Goel Colon & Rectal Surgery median Middle half National median
2019 $828 $443 $125–$2,179 $163
2020 $0 $167 $53–$931 $114
2021 $6,817 $207 $72–$1,272 $132
2022 $6,210 $341 $111–$1,587 $149
2023 $458 $322 $115–$1,420 $160
2024 $4,645 $328 $112–$1,354 $164
2025 $264 $317 $109–$1,248 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $18,817 55 payments
  2. Ethicon US, LLC $129 2 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $79 3 payments
  4. THD America, Inc. $54 4 payments
  5. Axonics Modulation Technologies, Inc. $41 2 payments
  6. W. L. Gore & Associates, Inc. $34 1 payment
  7. Davol Inc. $29 1 payment
  8. Acera Surgical, Inc. $20 1 payment
  9. Trevena, Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $13,500 5 payments
  2. Travel and Lodging $3,257 19 payments
  3. Food and Beverage $2,442 44 payments
  4. Gift $24 2 payments
Products named General payments · program years 2019–2025
  1. DAVINCI XI $7,500 3 payments
  2. Da Vinci Surgical System Surgery $6,000 2 payments
  3. Da Vinci Surgical System Surgery $5,317 50 payments
  4. Echelon Flex $129 2 payments
  5. GATTEX $79 3 payments
  6. Harmonic $76 1 payment
  7. Enseal $76 1 payment
  8. SURGICEL NU-KNIT $53 1 payment
  9. ECHELON ENDOPATH $53 1 payment
  10. Echelon Circular $53 1 payment
  11. Other $196 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

305

Median for Colorectal Surgery (Proctology): 106

Drug cost

$5,348

Median for Colorectal Surgery (Proctology): $1,614

Branded share of claims

69.2%

Median for Colorectal Surgery (Proctology): 35.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 98 $2,357
Enoxaparin Sodium Generic 13 $924
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 15 $792
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 70 $506
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 17 $292
Hydrocortisone Generic 24 $141
Metronidazole Generic 32 $115
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 11 $113
Neomycin Sulfate Generic 25 $108

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,507 Part D prescribers listed as Colorectal Surgery (Proctology); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$83,465

Medicare's payments for the services billed

Medicare patients

214

Average age 71

Services billed

622

119 women, 95 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 36%
Cancer 36%
Ischemic heart disease 31%
Chronic kidney disease 27%
Depression 23%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

70 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Colon & Rectal Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record